Suzanna Lee

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine

JCO Precision Oncology(2022)10.1200/po.20.00508

Top 22%

0.918DataRank

Top 22%17 citations

Ramez N. Eskander, Jason K. Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +8 more

Papers

Driven by 25 papers — median percentile 53. Top paper: “SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer”.

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer

JCI Insight(2021)10.1172/jci.insight.150453

N/A

2.2DataRank · unranked

68 citations

Shumei Kato, Hitendra Patel, Paul T. Fanta, Suzanna Lee, Ryosuke Okamura +2 more

Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens

JCI Insight(2021)10.1172/jci.insight.142547

N/A

1.1DataRank · unranked

31 citations

Ryosuke Okamura, Jacob J. Adashek, Noor Khalid, Suzanna Lee, Van Thomas Nguyen +3 more

Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine

JCO Precision Oncology(2022)10.1200/po.20.00508

Top 22%

0.918DataRank

Top 22%17 citations

Ramez N. Eskander, Jason K. Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +8 more

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies

npj Precision Oncology(2022)10.1038/s41698-022-00259-7

Top 71%

0.123DataRank

Top 71%1 citations

Razelle Kurzrock, Suzanna Lee, Ryosuke Okamura, Hyo Jeong Lim, Ki Hwan Kim +3 more

Targeting G1-S phase cell-cycle alterations with CDK4/6 inhibitor-based genomically matched personalized therapy approach.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3623

N/A

0DataRank · unranked

1 citations

Shumei Kato, Ryosuke Okamura, Noor Khalid, Suzanna Lee, Van Thomas Nguyen +3 more

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3761

N/A

0DataRank · unranked

41 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐freeDNAin invasive gliomas after treatment

International Journal of Cancer(2021)10.1002/ijc.33481

N/A

0DataRank · unranked

31 citations

David Piccioni, Amélie Boichard, Suzanna Lee, Rebecca E. Jimenez, Jason K. Sicklick +3 more

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy

npj Precision Oncology(2022)10.1038/s41698-022-00309-0

N/A

0DataRank · unranked

17 citations

Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Ramez N. Eskander +7 more

Multi‐omic analysis in carcinoma of unknown primary ( CUP ): therapeutic impact of knowing the unknown

Molecular Oncology(2022)10.1002/1878-0261.13293

N/A

0DataRank · unranked

12 citations

Sophia Gumas, Jacob J. Adashek, Ryosuke Okamura, Suzanna Lee, Jason K. Sicklick +2 more

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics

Cancer Medicine(2023)10.1002/cam4.6000

N/A

0DataRank · unranked

32 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De, Suzanna Lee +7 more

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

npj Genomic Medicine(2023)10.1038/s41525-023-00359-8

N/A

0DataRank · unranked

21 citations

Razelle Kurzrock, Nicholas Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla +8 more

Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity

Cancer Medicine(2023)10.1002/cam4.6844

N/A

0DataRank · unranked

13 citations

Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee +7 more

Data from Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

(2023)10.1158/1078-0432.c.6529977

N/A

0DataRank · unranked

0 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2614

N/A

0DataRank · unranked

0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

Viewing the immune checkpoint VISTA: landscape and outcomes across cancers

ESMO Open(2024)10.1016/j.esmoop.2024.102942

N/A

0DataRank · unranked

31 citations

Razelle Kurzrock, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee, Mina Nikanjam +10 more

Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy

iScience(2024)10.1016/j.isci.2024.110465

N/A

0DataRank · unranked

10 citations

Shumei Kato, Jordan S. Lim, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +6 more

High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy

iScience(2024)10.1016/j.isci.2024.109632

N/A

0DataRank · unranked

10 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists

Cancer Communications(2024)10.1002/cac2.12592

N/A

0DataRank · unranked

4 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +7 more

Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.2626

N/A

0DataRank · unranked

1 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +5 more

Tumor mutational burden, PD-1, negative Wnt/β-catenin regulators, and positive MHC class II antigen presentation regulators as predictors of longer survival after immune checkpoint inhibitors across cancers: A comprehensive analysis of 400 immunity biomarkers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2625

N/A

0DataRank · unranked

0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000438

N/A

0DataRank · unranked

191 citations

Shumei Kato, Suzanna Lee, Rebecca E. Jimenez, Jason K. Sicklick, Razelle Kurzrock +1 more

Natural killer cell transcriptomic expression and prediction of survival after immune checkpoint blockade across cancers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2518

N/A

0DataRank · unranked

0 citations

Daisuke Nishizaki, Suzanna Lee, Taylor J. Jensen, Shumei Kato, Paul DePietro +3 more

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Nature Communications(2020)10.1038/s41467-020-18613-3

N/A

0DataRank · unranked

303 citations

Ki Hwan Kim, Hyo Jeong Lim, Amélie Boichard, Mina Nikanjam, Elizabeth Weihe +17 more

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-20-0161

N/A

0DataRank · unranked

105 citations

Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee +9 more

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

OncoImmunology(2020)10.1080/2162402x.2019.1708065

N/A

0DataRank · unranked

68 citations

Ryosuke Okamura, Yuichi Kumaki, Sadakatsu Ikeda, Mina Nikanjam, Ramez N. Eskander +9 more

Suzanna Lee

Indexed papers

Top data-sharing exemplar

Papers